(Z)-2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine

• ChemBase ID: 179790
• Molecular Formular: C10H16N6S
• Molecular Mass: 252.33924
• Monoisotopic Mass: 252.11571554
• SMILES: N(=C(\NC)/NCCSCc1nc[nH]c1C)/C#N
• Canonical SMILES: N#C/N=C(\NCCSCc1nc[nH]c1C)/NC
• InChI: InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)
• InChIKey: AQIXAKUUQRKLND-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (Z)-2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
• IUPAC Traditional name: (Z)-2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
• Synonyms: Acitak; Acinil; Altramet; Azucimet; Cedine; Cimagen; Cimal; Cimetag; Cime; Cimeldine; Cimetimax; DuraH2; Dyspamet; Edalene; Galenamet; Gastromet; Magicul; Metracin; Neutromed; Neutronorm; Peptimax; Peptol; Phimetin; Sigmetadine; Tagamet; Tametin; Ulcedin; Ultek; Ulcometin; Ulcostad; Venopex; Zita; Cimetidine

Database IDs

• CAS Number: 51481-61-9
• PubChem SID: 164235700
• PubChem CID: 2756

CALCULATED PROPERTIES

• Acid pKa: 13.3825
• H Acceptors: 5
• H Donor: 3
• LogD (pH = 5.5): -1.023358
• LogD (pH = 7.4): -0.21932887
• Log P: -0.109356105
• Molar Refractivity: 70.3171 cm^3
• Polarizability: 25.88721 Å^3
• Polar Surface Area: 88.89 Å^2
• Rotatable Bonds: 5
• Lipinski's Rule of Five: true

PROPERTIES

Pharmacology Properties

• Mechanism of Action: Hepatic monooxygenase inhibitor; Histamine H2 receptor antagonist

Product Information

• Application(s): Anti-HIV; Used to treat peptic ulcers, duodenal ulcers, gastrointestinal bleeding and gastrooesophageal reflux disease

REFERENCES

• Brimblecombe, R.W. et al., Br. J. Pharmacol., 1975, 53, 435, (pharmacol)
• Durant, G.J. et al., J. Med. Chem., 1977, 20, 901, (synth)
• Brogden, R.N. et al., Drugs, 1978, 15, 93, (rev)
• Freston, J.W., Ann. Intern. Med., 1982, 97, 573, (rev, pharmacol)
• Wiseman, E.H. et al., Chron. Drug Discovery, 1982, 1, 173, (history, rev)
• Sorkin, E.M. et al., Drug Intell. Clin. Pharm., 1983, 17, 110, (drug interactions)
• Shibata, M. et al., J. Pharm. Sci., 1983, 72, 1436, (cryst struct)
• Bavin, P.M.G. et al., Anal. Profiles Drug Subst., 1984, 13, 127, (rev)
• Sastry, M.K. et al., Hind. Antibiot. Bull., 1985, 27, 16, (cmr)
• Brimblecombe, R.W. et al., Hum. Toxicol., 1985, 4, 13, (rev, tox)
• Hegedus, B. et al., J. Pharm. Biomed. Anal., 1985, 3, 303, (polymorphism)
• Gerber, M.C., Pharmacol. Ther., 1985, 27, 353, (drug interactions)
• Walker, T.F. et al., Hum. Toxicol., 1987, 6, 159, (tox)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 1721, (synonyms)
• Kirch, W., Pharmacol. Ther., 1987, 33, 129, (biochem)
• IARC Monog., 1990, 50, 235, (rev, tox)
• The Landmark Papers: The H2-Receptor Antagonists, (Ed. Pounder, R.E.), Science Press, 1990, (book)
• Russel, F.G. et al., J. Chromatogr., B: Biomed. Appl., 1994, 661, 173, (hplc)
• Hall, N., Chem. Br., Dec., 1997, 25, (rev)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 1183
• Middleton, D.A. et al., J.A.C.S., 2000, 122, 1161-1170, (polymorph)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, TAB250